Amgen Inc. $AMGN Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.7% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,193,464 shares of the medical research company’s stock after buying an additional 75,392 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Amgen were worth $333,227,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Parkside Financial Bank & Trust raised its stake in shares of Amgen by 5.6% during the second quarter. Parkside Financial Bank & Trust now owns 4,061 shares of the medical research company’s stock valued at $1,134,000 after purchasing an additional 214 shares during the period. Aviva PLC raised its position in shares of Amgen by 7.0% during the 2nd quarter. Aviva PLC now owns 401,906 shares of the medical research company’s stock worth $112,216,000 after purchasing an additional 26,292 shares during the period. BHK Investment Advisors LLC increased its holdings in shares of Amgen by 2.8% in the 2nd quarter. BHK Investment Advisors LLC now owns 2,734 shares of the medical research company’s stock worth $763,000 after acquiring an additional 75 shares during the period. Prospera Financial Services Inc lifted its holdings in Amgen by 5.9% in the second quarter. Prospera Financial Services Inc now owns 34,283 shares of the medical research company’s stock worth $9,575,000 after purchasing an additional 1,899 shares during the period. Finally, Summit Investment Advisors Inc. lifted its position in Amgen by 1.6% in the first quarter. Summit Investment Advisors Inc. now owns 23,660 shares of the medical research company’s stock worth $7,371,000 after purchasing an additional 369 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $320.20 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The company has a market capitalization of $172.38 billion, a price-to-earnings ratio of 26.18, a P/E/G ratio of 2.61 and a beta of 0.45. The stock’s fifty day simple moving average is $289.94 and its 200-day simple moving average is $288.50.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Bank of America boosted their target price on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. The Goldman Sachs Group decreased their price target on shares of Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a research report on Wednesday. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company raised their price objective on Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Guggenheim boosted their target price on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research report on Thursday. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $308.83.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.